Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Gastrointestinal Therapeutics Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Type I Market Performance (Volume)
  • 2.1.2 Type II Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Type I Market Performance (Value)
  • 2.1.2 Type II Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 IBD Market Performance (Volume)
  • 3.1.2 Irritable Bowel Syndrome (IBS) Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 AbbVie
  • 4.1.1 AbbVie Profiles
  • 4.1.2 AbbVie Product Information
  • 4.1.3 AbbVie Gastrointestinal Therapeutics Business Performance
  • 4.1.4 AbbVie Gastrointestinal Therapeutics Business Development and Market Status
• 4.2 Allergan
  • 4.2.1 Allergan Profiles
  • 4.2.2 Allergan Product Information
  • 4.2.3 Allergan Gastrointestinal Therapeutics Business Performance
  • 4.2.4 Allergan Gastrointestinal Therapeutics Business Development and Market Status
• 4.3 Johnson & Johnson
  • 4.3.1 Johnson & Johnson Profiles
  • 4.3.2 Johnson & Johnson Product Information
  • 4.3.3 Johnson & Johnson Gastrointestinal Therapeutics Business Performance
  • 4.3.4 Johnson & Johnson Gastrointestinal Therapeutics Business Development and Market Status
• 4.4 Takeda
  • 4.4.1 Takeda Profiles
  • 4.4.2 Takeda Product Information
  • 4.4.3 Takeda Gastrointestinal Therapeutics Business Performance
  • 4.4.4 Takeda Gastrointestinal Therapeutics Business Development and Market Status
• 4.5 Novartis
  • 4.5.1 Novartis Profiles
  • 4.5.2 Novartis Product Information
  • 4.5.3 Novartis Gastrointestinal Therapeutics Business Performance
  • 4.5.4 Novartis Gastrointestinal Therapeutics Business Development and Market Status
• 4.6 Pfizer
  • 4.6.1 Pfizer Profiles
  • 4.6.2 Pfizer Product Information
  • 4.6.3 Pfizer Gastrointestinal Therapeutics Business Performance
  • 4.6.4 Pfizer Gastrointestinal Therapeutics Business Development and Market Status
• 4.7 Merck
  • 4.7.1 Merck Profiles
  • 4.7.2 Merck Product Information
  • 4.7.3 Merck Gastrointestinal Therapeutics Business Performance
  • 4.7.4 Merck Gastrointestinal Therapeutics Business Development and Market Status
• 4.8 F. Hoffmann-La Roche
  • 4.8.1 F. Hoffmann-La Roche Profiles
  • 4.8.2 F. Hoffmann-La Roche Product Information
  • 4.8.3 F. Hoffmann-La Roche Gastrointestinal Therapeutics Business Performance
  • 4.8.4 F. Hoffmann-La Roche Gastrointestinal Therapeutics Business Development and Market Status
• 4.9 Eli Lilly
  • 4.9.1 Eli Lilly Profiles
  • 4.9.2 Eli Lilly Product Information
  • 4.9.3 Eli Lilly Gastrointestinal Therapeutics Business Performance
  • 4.9.4 Eli Lilly Gastrointestinal Therapeutics Business Development and Market Status
• 4.10 AstraZeneca
  • 4.10.1 AstraZeneca Profiles
  • 4.10.2 AstraZeneca Product Information
  • 4.10.3 AstraZeneca Gastrointestinal Therapeutics Business Performance
  • 4.10.4 AstraZeneca Gastrointestinal Therapeutics Business Development and Market Status
• 4.11 Procter & Gamble
• 4.12 Tillotts Pharma
• 4.13 Johnson & Johnson
• 4.14 Takeda
• 4.15 Novartis

5 Market Performance for Manufacturers

• 5.1 Global Gastrointestinal Therapeutics Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Global Gastrointestinal Therapeutics Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Global Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Global Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 USA Market Performance for Manufacturers
  • 6.2.1 USA Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 USA Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 USA Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 USA Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 Europe Market Performance for Manufacturers
  • 6.3.1 Europe Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 Europe Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 Europe Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 Europe Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Japan Market Performance for Manufacturers
  • 6.4.1 Japan Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Japan Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Japan Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Japan Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Korea Market Performance for Manufacturers
  • 6.5.1 Korea Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Korea Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Korea Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Korea Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 India Market Performance for Manufacturers
  • 6.6.1 India Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 India Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 India Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 India Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Southeast Asia Market Performance for Manufacturers
  • 6.7.1 Southeast Asia Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Southeast Asia Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Southeast Asia Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Southeast Asia Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 South America Market Performance for Manufacturers
  • 6.8.1 South America Gastrointestinal Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 South America Gastrointestinal Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 South America Gastrointestinal Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 South America Gastrointestinal Therapeutics Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Global Gastrointestinal Therapeutics Market Performance (Sales Point)

• 7.1 Global Gastrointestinal Therapeutics Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Global Gastrointestinal Therapeutics Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Global Gastrointestinal Therapeutics Price (USD/Unit) by Regions 2013-2018
• 7.4 Global Gastrointestinal Therapeutics Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Global Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 USA Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 Europe Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Japan Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Korea Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 India Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Southeast Asia Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Southeast Asia Gastrointestinal Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 IBD Industry
• 11.2 Irritable Bowel Syndrome (IBS) Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Global Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Global Gastrointestinal Therapeutics Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 China Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 USA Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 Europe Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Japan Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Korea Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 India Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Southeast Asia Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 South America Gastrointestinal Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Type I Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Type II Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 IBD Sales and and Growth Rate 2019-2024
  • 12.4.3 Irritable Bowel Syndrome (IBS) Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Global Gastrointestinal Therapeutics Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Global Gastrointestinal Therapeutics Gross Profit Trend 2019-2024

13 Conclusion

Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Gastrointestinal Therapeutics for these regions, from 2012 to 2023 (forecast), covering
China
USA
Europe
Japan
Korea
India

Global Gastrointestinal Therapeutics market competition by top manufacturers/players, with Gastrointestinal Therapeutics sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
AbbVie
Allergan
Johnson & Johnson
Takeda
Novartis
Pfizer
Merck
F. Hoffmann-La Roche
Eli Lilly
AstraZeneca
Procter & Gamble
Tillotts Pharma
Shire Pharmaceuticals
GlaxoSmithKline
RedHill Biopharma
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Type I
Type II
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Gastrointestinal Therapeutics for each application, including
IBD
Irritable Bowel Syndrome (IBS)

If you have any special requirements, please let us know and we will offer you the report as you want.